
TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) – Investment analysts at HC Wainwright decreased their FY2026 EPS estimates for TScan Therapeutics in a research note issued to investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.84) per share for the year, down from their prior estimate of ($0.62). HC Wainwright currently has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q4 2026 earnings at ($0.13) EPS, Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.09) EPS, Q4 2027 earnings at ($0.09) EPS, FY2027 earnings at ($0.37) EPS, FY2028 earnings at ($0.28) EPS and FY2029 earnings at ($0.28) EPS.
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06). TScan Therapeutics had a negative net margin of 2,219.19% and a negative return on equity of 119.44%. The business had revenue of $0.59 million for the quarter, compared to analyst estimates of $0.46 million.
Other equities analysts also recently issued research reports about the company. Lifesci Capital downgraded TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Benchmark restated a “buy” rating on shares of TScan Therapeutics in a research report on Thursday, August 13th. Weiss Ratings downgraded TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Finally, Wedbush lowered TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research report on Wednesday, September 2nd. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, TScan Therapeutics currently has a consensus rating of “Hold” and an average target price of $2.67.
Get Our Latest Research Report on TScan Therapeutics
TScan Therapeutics Price Performance
Shares of TScan Therapeutics stock opened at $0.15 on Tuesday. The firm has a market cap of $9.83 million, a PE ratio of -0.16 and a beta of 1.21. TScan Therapeutics has a twelve month low of $0.15 and a twelve month high of $1.47. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.31. The business has a 50-day moving average price of $0.25 and a 200 day moving average price of $0.80.
Institutional Investors Weigh In On TScan Therapeutics
Institutional investors have recently bought and sold shares of the company. Landscape Capital Management L.L.C. purchased a new stake in TScan Therapeutics during the 2nd quarter worth approximately $25,000. Public Employees Retirement System of Ohio acquired a new position in shares of TScan Therapeutics during the first quarter valued at approximately $28,000. Bank of America Corp DE purchased a new position in shares of TScan Therapeutics in the second quarter valued at approximately $48,000. Kestra Advisory Services LLC purchased a new position in shares of TScan Therapeutics in the first quarter valued at approximately $63,000. Finally, NewEdge Wealth LLC purchased a new position in shares of TScan Therapeutics in the second quarter valued at approximately $90,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.
TScan Therapeutics Company Profile
TScan Therapeutics is a clinical-stage biotechnology company developing engineered T cell receptor (TCR) T cell therapies for cancer. Its approach is designed to equip a patient’s T cells to recognize and attack cancer cells bearing specific targets. The company’s research and development programs include therapies for blood cancers and solid tumors. TScan uses its technology platform to identify cancer-associated targets and develop TCRs directed at them, with the goal of creating treatments for patients whose cancers express those targets.
Featured Articles
- Five stocks we like better than TScan Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
